Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > New Analyst update calling AGN.C a SPEC BUY with $25 target
View:
Post by SkynetMoney on Jul 18, 2022 3:29pm

New Analyst update calling AGN.C a SPEC BUY with $25 target

New Analyst update calling AGN.C a SPEC BUY with $25 target

 

Here's a screenshot from my broker this morining... Could bring lots of attention

Comment by SkynetMoney on Jul 18, 2022 3:32pm
Screenshot didnt work   Breathing Easier - Liftoff! - IPF Phase 2a Data Hits ACTION: Maintaining SPECULATIVE BUY Rating and Target Price AGN reported topline results of a Phase 2a trial with ifenprodil in IPF patients with chronic cough - the idiopathic pulmonary fibrosis (IPF) data hit its endpoint -showing promising initial efficacy. We are maintaining a SPECULATIVE BUY rating. Our ...more  
Algernon Pharmaceuticals Inc.